New Protocols Under development - As of January 31, 2026

Disease	Title/PI	Planned Activation
CTEP studies		
BN	**NRG-BN015:** Randomized phase 3 clinical trial of postoperative radiotherapy versus postoperative surveillance for clinical low-risk, molecular high-risk meningioma and longitudinal surveillance for clinical and molecular low-risk meningioma	Q4 2026
GI	**NRG-GI013:** Ablative Radiation Therapy To Liver Metastases For Immuno-Oncology (IO) Response in Microsatellite Stable (MSS) Colon Cancer (the RADIO study)	Q3 2026
GYN	**NRG-GY035: Randomized** Phase II/III Trial of Carboplatin, Paclitaxel, Pembrolizumab vs. Carboplatin, Paclitaxel, Bevacizumab vs. Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer	**Activated January 12, 20226**
GYN	**NRG-GY038:** A Phase II trial of sacituzumab govitecan (SG) and bevacizumab versus standard of care carboplatin, liposomal doxorubicin and bevacizumab in patients with platinum-sensitive ovarian cancer that has progressed on prior maintenance PARP inhibitor therapy	Q3 2026
GYN	**NRG-GY039**: A Phase III Non-Inferiority Trial of Hypofractionated Chemoradiation Therapy Versus Standard Chemoradiation for Cervical Cancer	Q1/Q2 2027
HN	**NRG-HN015**: A randomized phase II trial of chemo-immunotherapy or immunotherapy in patients with recurrent/persistent PD-L1-enriched squamous cell carcinoma of the head and neck undergoing salvage surgery	**Activated January 12, 20226**
HN	**NRG-HN016**: Randomized Phase II Trial of Radiotherapy with Concurrent Cetuximab vs. Carboplatin and Paclitaxel in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin	Q2/Q3 2026
LU	**NRG-LU011:** A Phase II Randomized Study of Reirradiation for Locally Recurrent Non-Small Cell Lung Cancer	Q3/Q4 2026
NCORP	**NRG-CC016**: ABCD RT Trial: Analysis of Biosignature Classification for DCIS Radiotherapy	Q1/Q2 2026
NCORP	**NRG-CC017: A** Randomized Phase II/III Study Comparing Temporally Modulated Pulsed Radiation Therapy (TMPRT) Versus Standard Radiation Therapy with Temozolomide for Elderly Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma to Prolong Symptom Deterioration-Free Survival	Q1/Q2 2026